ELTX
$10.85-1.13 (-9.43%)
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate is ELI-002, a multivalent lymph node–targeted amphiphile (AMP) peptide vaccine that is in Phase II cli...
Recent News
Is Aura Biosciences (AURA) Outperforming Other Medical Stocks This Year?
Here is how Aura Biosciences, Inc. (AURA) and Elicio Therapeutics (ELTX) have performed compared to their sector so far this year.
Wall Street Analysts Predict a 42.28% Upside in Elicio Therapeutics (ELTX): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 42.3% in Elicio Therapeutics (ELTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Elicio Therapeutics: Q4 Earnings Snapshot
BOSTON (AP) — Elicio Therapeutics, Inc. ELTX) on Thursday reported a loss of $7.7 million in its fourth quarter. The Boston-based company said it had a loss of 49 cents per share.
While insiders own 33% of Elicio Therapeutics, Inc. (NASDAQ:ELTX), individual investors are its largest shareholders with 55% ownership
Key Insights Elicio Therapeutics' significant individual investors ownership suggests that the key decisions are...
Elicio Therapeutics (ELTX) Upgraded to Buy: Here's Why
Elicio Therapeutics (ELTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).